Agios Pharmaceuticals (FRA:8AP) Tariff Resilience Score: 8/10 (As of Jul. 03, 2026)


FRA:8AP Agios Pharmaceuticals Inc FRA:8AP
44 GF Score
Price €32.20
GF Value €72.27
! 4 Warning Signs
View Full Analysis

What is Agios Pharmaceuticals Tariff Resilience Score?

Agios Pharmaceuticals FRA:8AP +0.63% 44 Tariff Resilience Score is 8 as of Jul. 03, 2026. GuruFocus rates FRA:8AP with a GF Score™ of 44/100 and a GF Value™ of €72.27. The stock has 4 warning signs investors should review. Among 1,373 Biotechnology companies, Agios Pharmaceuticals ranks better than 98.69% on this metric.

Agios Pharmaceuticals has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Agios Pharmaceuticals has Agios Pharmaceuticals Inc has low tariff exposure due to its focus on drug development. Its supply chain is less reliant on international trade, and it benefits from industry-specific exemptions on medical products.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Agios Pharmaceuticals might have Highly Resilient.

Agios Pharmaceuticals  (FRA:8AP) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Agios Pharmaceuticals Tariff Resilience Score Related Terms

FRA:8AP vs ABCL, KOD, IMNM: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Agios Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agios Pharmaceuticals Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Tariff Resilience Score falls into.


FRA:8AP
44GF Score
Agios Pharmaceuticals Inc FRA:8AP
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Agios Pharmaceuticals (FRA:8AP) has a Tariff Resilience Score of 8 as of Jul. 03, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Agios Pharmaceuticals ranks #18 out of 1373 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Agios Pharmaceuticals' Tariff Resilience Score too high?
Agios Pharmaceuticals' current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Agios Pharmaceuticals' value of 8 is 100% above this industry median. Based on the distribution chart, Agios Pharmaceuticals ranks #18 out of 1373 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Agios Pharmaceuticals has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' Tariff Resilience Score compare to ABCL and KOD?
According to the Biotechnology industry distribution chart, Agios Pharmaceuticals ranks #18 out of 1373 companies for Tariff Resilience Score. This places Agios Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Agios Pharmaceuticals' value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,373 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Agios Pharmaceuticals's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agios Pharmaceuticals's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Agios Pharmaceuticals (FRA:8AP) has a current Tariff Resilience Score of 8. The stock's GF Value™ is €72.27, compared to a current price of €32.20 — trading 55.4% below its estimated fair value. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Agios Pharmaceuticals' overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Agios Pharmaceuticals (FRA:8AP), the current Tariff Resilience Score is 8 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Agios Pharmaceuticals (FRA:8AP) Overvalued in 2026?

Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued. The current stock price of €32.20 is trading 55.4% below its estimated GF Value™ of €72.27.

Key valuation signals for FRA:8AP:

  • Tariff Resilience Score: 8
  • GF Value™: €72.27 vs. price of €32.20 (55.4% below fair value)
  • GF Score™: 44/100 with 4 warning signs
  • Industry Position: 100% above the Biotechnology median (#18 of 1373)

No single metric tells the full story. See the FRA:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Agios Pharmaceuticals Business Description

Other Exchanges AGIO:USA0HB0:UK8AP:Germany
Address 88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
44GF Score

Get the complete analysis for FRA:8AP

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.20
Price
€72.27
GF Value